Crestwood Advisors Group LLC Cuts Stock Position in Stryker Corporation $SYK

Crestwood Advisors Group LLC lowered its stake in Stryker Corporation (NYSE:SYK) by 12.1% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 51,730 shares of the medical technology company’s stock after selling 7,136 shares during the period. Crestwood Advisors Group LLC’s holdings in Stryker were worth $20,466,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently modified their holdings of the stock. Mar Vista Investment Partners LLC boosted its stake in Stryker by 10.2% during the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock valued at $33,572,000 after purchasing an additional 8,353 shares during the last quarter. United Services Automobile Association purchased a new stake in Stryker during the 1st quarter valued at $2,857,000. AXS Investments LLC boosted its stake in Stryker by 13.7% during the 1st quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock valued at $3,286,000 after purchasing an additional 1,062 shares during the last quarter. Park Edge Advisors LLC purchased a new stake in shares of Stryker during the second quarter valued at $679,000. Finally, Hendley & Co. Inc. boosted its position in shares of Stryker by 60.3% during the second quarter. Hendley & Co. Inc. now owns 14,018 shares of the medical technology company’s stock valued at $5,546,000 after buying an additional 5,274 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider directly owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.90% of the company’s stock.

Stryker Stock Performance

SYK opened at $362.74 on Wednesday. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The company has a market cap of $138.68 billion, a price-to-earnings ratio of 48.05, a PEG ratio of 2.66 and a beta of 0.94. The company’s 50 day moving average is $376.79 and its 200 day moving average is $381.24. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, equities research analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were given a dividend of $0.84 per share. The ex-dividend date was Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s payout ratio is 44.15%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Needham & Company LLC increased their price objective on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Rothschild & Co Redburn assumed coverage on shares of Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target on the stock. Weiss Ratings restated a “buy (b-)” rating on shares of Stryker in a report on Wednesday, October 8th. UBS Group set a $408.00 target price on shares of Stryker in a report on Monday, October 13th. Finally, Barclays raised their target price on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Fourteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $433.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.